Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech
Collaboration to develop a first-in-class α9/α10 nicotinic acetylcholine receptor antagonist for the treatment of chronic pain Kineta to receive undisclosed upfront payment and up to $359 million in ...
Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech
Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech Collaboration to develop a first-in-class α9/α10 nicotinic acetylcholine receptor antagonist for the treatme ...
Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models
Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models Small molecule RIG-I agonist induces innate immune responses, immunogenic tumor cell death and in vivo pr ...
Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference
Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference New data on Kineta’s small molecule RIG-I agonists in tumor mode ...